从资金流向上来看，当日医疗美容板块主力资金净流出5875.57万元，游资资金净流入1690.61万元，散户 资金净流入4184.96万元。医疗美容板块个股资金流向见下表： 证券之星消息，11月24日医疗美容板块较上一交易日上涨0.27%，*ST美谷领涨。当日上证指数报收于 3836.77，上涨0.05%。深证成指报收于12585.08，上涨0.37%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 4.07 | 4.63% | 28.52万 | | 1.15亿 | | 688363 | 华熙生物 | 49.78 | 1.86% | 1.87万 | | 9268.75万 | | 300896 | 爱美客 | 66'56 | -1.36% | 2.41万 | | 3.52亿 | | 920982 | 锦波生物 | 216.59 | -1.55% | 7336.92 | | 1.60亿 | | 代码 | 名称 | 主力净流 ...

Core Viewpoint - The company is focusing on strategic upgrades through branding, chain expansion, and digitalization to enhance its market position and profitability, supported by both organic growth and acquisitions [1][2]. Group 1: Company Strategy - The company held a strategic upgrade conference, introducing three main strategies: "super brand, super chain, and super digitalization" [1]. - Branding efforts will include upgrading service processes, enhancing brand promotion, and collaborating with high-end real estate and well-known brands to increase brand visibility [1]. - The chain strategy aims to deepen presence in 20 key economically developed cities in China, increasing the number of cities with annual revenues exceeding 100 million yuan from 8 to 12, and boosting revenues in Beijing and Shanghai from over 600 million yuan to over 1 billion yuan [1]. - Digitalization initiatives involve a self-developed team creating 38 digital systems, with a self-research ratio of 70%, aimed at improving operational efficiency through precise marketing and restructured customer interaction processes [1]. Group 2: Recent Acquisitions - The company announced the acquisition of 19 Naieryer franchise stores in Zhuhai and Dongguan for 40 million yuan, which will add 19 new stores to its direct operation, including 2 medical beauty and 17 beauty stores [2]. - This acquisition is expected to generate approximately 75 million yuan in new revenue and 7.5 million yuan in net profit after tax for the group [2]. Group 3: Shareholder Returns and Financial Outlook - The company has launched a long-term shareholder return plan, committing up to 1.2 billion HKD over the next three years, including annual dividends of no less than 50% of net profit attributable to shareholders and share buybacks [2]. - Based on operational efficiency improvements, the profit forecast for 2025-2026 has been raised by 5% and 8% to 300 million and 360 million yuan, respectively, with current stock prices reflecting a P/E ratio of 20x and 17x for 2025-2026 [2].

近日，三生制药发布公告称，公司建议将附属公司蔓迪股份分拆并于联交所主板独立上市。建议分拆 （倘进行）预计将通过本公司按董事会为确定股东权利而厘定的记录日期，根据股东各自于本公司的持 股比例，以实物分派方式向股东分派其持有的蔓迪全部股份及蔓迪新股的全球发售，包括香港公开发售 及国际发售。 2025年11月20日，蔓迪已向联交所递交申请，以实物分派本公司持有的蔓迪全部股份及全球发售蔓迪新 股的方式，批准蔓迪股份在联交所主板上市。蔓迪上市文件的经编纂申请版本（「申请版本」）刊载于 联交所网站以供阅览及下载。 蔓迪是一家在开曼群岛注册成立的获豁免有限公司，且为三生制药公司的附属公司。于公告日期，蔓迪 由本公司、英泰管理有限公司、MandiGroupLimited、GLWecanInvestmentIVL.P.及阿里健康（香港）科 技有限公司实益拥有约87.16%、3.38%、2.80%、4.00%及2.65%的权益。 药师帮：第三季度收入同比增长15%，致力于推出高质量自有品牌产品 近日，药师帮发布公告称，截至2025年9月30日止三个月，公司连同其附属公司及综合联属实体的收入 同比增长15%。这一增长超过了2025 ...

Market Overview - The medical beauty sector experienced a decline of 2.01% on November 21, with *ST Meigu leading the drop [1] - The Shanghai Composite Index closed at 3834.89, down 2.45%, while the Shenzhen Component Index closed at 12538.07, down 3.41% [1] Stock Performance - Key stocks in the medical beauty sector showed the following performance: - Huaxi Biological (688363) closed at 48.87, down 1.81% with a trading volume of 25,700 shares and a turnover of 126 million yuan [1] - Aimeike (300896) closed at 148.00, down 1.88% with a trading volume of 29,100 shares [1] - Jinbo Biological (920982) closed at 220.01, down 4.88% with a trading volume of 11,000 shares [1] - *ST Meigu (000615) closed at 3.89, down 4.89% with a trading volume of 217,100 shares and a turnover of 85.48 million yuan [1] Capital Flow - The medical beauty sector saw a net outflow of 87.65 million yuan from main funds, while retail investors contributed a net inflow of 83.50 million yuan [1] - Detailed capital flow for key stocks includes: - *ST Meigu: Main funds net outflow of 12.38 million yuan, retail net inflow of 9.03 million yuan [2] - Huaxi Biological: Main funds net outflow of 24.09 million yuan, retail net inflow of 26.09 million yuan [2] - Jinbo Biological: Main funds net outflow of 32.71 million yuan, retail net inflow of 340,200 yuan [2] - Aimeike: Main funds net outflow of 51.18 million yuan, retail net inflow of 48.38 million yuan [2]

智通财经APP获悉，中金发布研报称，基于美丽田园医疗健康(02373)经营提效，上调25-26年归母净利 润预测5%/8%至3.0/3.6亿元，当前股价对应25-26年20/17x P/E。维持跑赢行业评级及目标价42港元，对 应25-26年30/25x P/E，有49%上行空间。该行认为公司已通过"三强联合"巩固龙头地位，后续有望通过 品牌化、连锁化、数字化升级，进一步强化影响力、扩大市场份额、提升盈利能力，看好公司内生增长 与外延并购共同驱动下的成长空间。 中金主要观点如下： 进一步收购奈瑞儿19家加盟门店，拓展大湾区覆盖、增厚收入利润 公司公告以4,000万元人民币收购珠海和东莞的19家奈瑞儿加盟门店，收购完成后，奈瑞儿正式将珠海 和东莞纳入直营区域，将带动公司直营门店新增19家，含2家医美及17家生美门店，从而推动集团在大 湾区核心城市的辐射密度进一步加深，公司预计有望为集团新增近7,500万元收入、750万元税后净利 润。 积极提升股东回报，看好内生+外延驱动下的广阔空间 公司近期发布长期股东回报计划：未来三年将动用最高12亿港币提供股东回报，包括每年派息不低于归 母净利润50%及回购公司股份。该行 ...

公司近期发布长期股东回报计划：未来三年将动用最高12亿港币提供股东回报，包括每年派息不低于归 母净利润50%及回购公司股份。该行看好公司内生+外延驱动下的广阔空间。 风险提示：行业竞争加剧;医疗事故风险;商誉减值风险。 发布战略升级，品牌化、连锁化、数字化驱动中长期成长 公司公告以4,000万元人民币收购珠海和东莞的19家奈瑞儿加盟门店，收购完成后，奈瑞儿正式将珠海 和东莞纳入直营区域，将带动公司直营门店新增19家，含2家医美及17家生美门店，从而推动集团在大 湾区核心城市的辐射密度进一步加深，公司预计有望为集团新增近7,500万元收入、750万元税后净利 润。 中金发布研报称，基于美丽田园医疗健康(02373)经营提效，上调25-26年归母净利润预测5%/8%至 3.0/3.6亿元，当前股价对应25-26年20/17x P/E。维持跑赢行业评级及目标价42港元，对应25-26年30/25x P/E，有49%上行空间。该行认为公司已通过"三强联合"巩固龙头地位，后续有望通过品牌化、连锁 化、数字化升级，进一步强化影响力、扩大市场份额、提升盈利能力，看好公司内生增长与外延并购共 同驱动下的成长空间。 积极提升股 ...

证券之星消息，11月20日医疗美容板块较上一交易日下跌2.32%，爱美客领跌。当日上证指数报收于 3931.05，下跌0.4%。深证成指报收于12980.82，下跌0.76%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 920982 | 锦波生物 | 231.29 | -0.55% | 6140.7 | | 1.43 Z | | 000615 | *ST美谷 | 4.09 | -1.21% | 26.65万 | | 1.09亿 | | 688363 | 华熙生物 | 49.77 | -1.54% | 2.02万 | | 1.01亿 | | 300896 | 爱美客 | 150.84 | -3.00% | 3.16万 | | 4.81亿 | 从资金流向上来看，当日医疗美容板块主力资金净流出1.04亿元，游资资金净流入1721.0万元，散户资金 净流入8685.88万元。医疗美容板块个股资金流向见下表： | 代码 | 名称 | 主力净流入 (元) | ...

Core Insights - The medical beauty sector experienced a slight increase of 0.23% on November 19, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Sector Performance - Ai Meike (300896) closed at 155.51, up 0.58% with a trading volume of 24,500 and a transaction value of 3.83 billion [1] - Huaxi Biological (688363) closed at 50.55, up 0.30% with a trading volume of 16,100 and a transaction value of 81.47 million [1] - Jinbo Biological (920982) closed at 232.56, down 0.97% with a trading volume of 5,813.42 and a transaction value of 136 million [1] - *ST Meigu (000615) closed at 4.14, down 3.72% with a trading volume of 402,400 and a transaction value of 1.671 billion [1] Capital Flow - The medical beauty sector saw a net inflow of 1.9441 million from institutional investors, while retail investors experienced a net outflow of 12.0117 million [1] - Detailed capital flow for individual stocks shows Ai Meike with a net inflow of 26.5772 million from institutional investors, while *ST Meigu had a significant net outflow of 24.8225 million [2]

美丽田园医疗健康(2373.HK)现涨4.88%至28.38港元，市值66.7亿港元。消息面上，美丽田园医疗健康公 告，其非全资附属公司奈瑞儿医疗器械及奈瑞儿健康管理已与广州蓓旻晟企业管理有限公司签署股权转 让协议。根据协议，卖方拟向买方转让目标业务——包括东莞及珠海相关标的的全部股权，交易总代价 为人民币4000万元。交易完成后，美丽田园将持有目标公司90%股权，使其成为集团的非全资附属公 司。 此次收购将为美丽田园带来19家直营门店的新增版图，其中包含2家医疗美容门店及17家生活美容门 店，直营门店总规模进一步拓展，大湾区核心城市辐射密度将进一步加深，同步带动集团收入的显着提 升。(格隆汇) ...

11月19日，朗姿股份涨6.28%，截至发稿，报22.84元/股，成交3.33亿元，换手率5.92%，总市值101.05 亿元。朗姿股份股价已经连续3天上涨，区间累计涨幅3.22%。 南方中证1000ETF（512100）基金经理为崔蕾。 截至发稿，崔蕾累计任职时间7年14天，现任基金资产总规模1227.6亿元，任职期间最佳基金回报 180.57%， 任职期间最差基金回报-15.93%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 资料显示，朗姿股份有限公司位于北京市朝阳区西大望路27号大郊亭南街3号院1号楼(朗姿大厦)，成立 日期2006年11月9日，上市日期2011年8月30日，公司主营业务涉及品牌女装的设计、生产与销售。主营 业务收入构成为：非手术类医疗美容41.59%，女装裙子11.34%，女装上衣11.22%，婴童服装10.90%， 女装外套9.55%，手术类医疗美容6.21%，婴童用品4.70%，女装裤子3.31%，其他1.18%。 从 ...